Navigation Links
Byetta Lawsuit News: Bernstein Liebhard LLP Notes Establishment of Multidistrict Litigation For Federal Lawsuits Involving Byetta, Similar Diabetes Drugs
Date:8/27/2013

New York, New York (PRWEB) August 27, 2013

Byetta lawsuits (http://www.byettalawsuit2013.com/), as well as all other federally-filed product liability claims involving the incretin mimetic class of diabetes drugs, have been transferred to the U.S. District Court, Southern District of California, for pretrial proceedings, Bernstein Liebhard LLP reports. According to a Transfer Order issued by the U.S. Judicial Panel on Multidistrict Litigation (JPML) on August 26, 2013, the consolidated proceeding will be presided over by the Honorable Anthony J. Battaglia. All of the claims pending in the newly-established multidistrict litigation involve allegations of a possible association between incretin mimetics, including Byetta, and pancreatic cancer. (In Re: Incretins Products Liability, Sales and Marketing Litigation, MDL 2452)

“Our Firm has received numerous inquiries from patients who used Byetta and other diabetes drugs in this class, and who are concerned that these medications resulted in their pancreatic cancer diagnosis. We agree that a consolidated proceeding will provide an efficient means of resolving claims involving incretin mimetics, including Byetta lawsuits,” says Bernstein Liebhard LLP, a nationwide law firm representing victims of defective drugs and medical devices. The Firm is offering free legal evaluations to alleged victims of Byetta pancreatic cancer, as well as pancreatitis and thyroid cancer.

Byetta and Pancreatic Cancer
Byetta and other incretin mimetics work to regulate insulin production in the pancreas by mimicking the action of incretin, a hormone produced in the intestinal tract. However, since its launch in 2005, the U.S. Food & Drug Administration (FDA) has released a number of Byetta warnings regarding the medication’s potentially harmful effects on the pancreas. In 2008, for example, the agency revealed that Byetta had been associated with a high number of adverse event reports involving pancreatitis.* Concerns about Byetta and pancreatic cancer were heightened after March 14, 2013, when the FDA announced it was investigating findings from an unpublished study that suggested drugs like Byetta could be associated with pre-cancerous cellular changes in the pancreas called pancreatic duct metaplasia.

In April 2013, the Institute for Safe Medicine Practices reported that incretin mimetics like Byetta were 25 times more likely to be associated with reports of pancreatic cancer compared to other classes of diabetes medications. According to the group, its analysis of FDA adverse event reports recorded during the 12 month period that ended in June 2012 also revealed that Byetta had been associated with 263 reports of pancreatitis, 71 cases of pancreatic cancer, and 14 incidents of thyroid cancer.** Most recently, a report published June 10th in the British Medical Journal revealed previously unpublished data that indicated the manufacturers of incretin mimetics may have downplayed the drugs’ potential to harm the pancreas.***

Court documents indicate that at least 53 lawsuits have been filed on behalf of patients who developed pancreatic cancer, allegedly due to their use of Byetta and other incretin mimetics. A multidistrict litigation, such as the one established for these claims, consolidates all lawsuits involving common questions of fact in one jurisdiction for coordinated pretrial proceedings. The aim of a multidistrict litigation is to avoid duplicative discovery and inconsistent rulings across similar claims, and to conserve the resources of the court, parties and witnesses.

Alleged victims of Byetta and pancreatic cancer, pancreatitis or thyroid cancer may be entitled to compensation for medical bills and other damages. Learn More about the possible link between Byetta and pancreatic cancer at Bernstein Liebhard LLP’s website. For a free Byetta lawsuit review, please call 800-511-5092.

*fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm124713.htm, FDA, August 18, 2008
**ismp.org/QuarterWatch/pdfs/2012Q3.pdf, ISMP, April 2013
***bmj.com/open-data/incretin#alternate; BMJ, June 10, 2013

About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993, including those who have been harmed by dangerous drugs, defective medical devices and consumer products. The firm has been named by The National Law Journal to the “Plaintiffs’ Hot List,” recognizing the top plaintiffs’ firms in the country, for the past 10 consecutive years.

Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
800-511-5092

ATTORNEY ADVERTISING. © 2013 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Contact Information:
Felecia L. Stern, Esq.
Bernstein Liebhard LLP
info (at) consumerinjurylawyers (dot) com
http://www.byettalawsuit2013.com/

Read the full story at http://www.prweb.com/releases/byetta-lawsuit/byetta-pancreatic-cancer/prweb11065921.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Federal Judicial Panel Considering Byetta Lawsuit Consolidation, Rottenstein Law Group LLP Reports
2. Byetta Pancreatic Cancer Allegation Lawsuits Update: Resource4thePeople Awaiting Federal Court Decision on Possible Creation of Multidistrict Litigation
3. Byetta Lawsuit Investigation Being Conducted by Bernstein Liebhard LLP On Behalf of Byetta Users Diagnosed with Pancreatic Cancer, Pancreatitis, and Thyroid Cancer
4. Byetta Lawsuit - Claims Move Forward, as Panel Considers Consolidation of Federal Claims Involving Byetta and Similar Diabetes Drugs, Bernstein Liebhard LLP Reports
5. Byetta Lawsuit News: Bernstein Liebhard LLP Awaits Decision on Establishment of Federal Multidistrict Litigation for Byetta Pancreatic Cancer Claims
6. Federal Byetta, Victoza, Januvia Lawsuits Could See Consolidation This Month, Rottenstein Law Group LLP Reports
7. Rottenstein Law Group LLP Acknowledges BMJ Study of Risks of Byetta, Januvia
8. Byetta Pancreatic Cancer Lawsuit News: Bernstein Liebhard LLP Comments on BMJ Investigation Finding Incretin Mimetic Risks Were Downplayed
9. Rottenstein Law Group LLP Comments on Drugmakers’ Cooperation With Safety Review of Byetta, Januvia, Victoza
10. Diabetes Drug Byetta Caused Arkansas Man’s Pancreatic Cancer and Resulting Injuries, Alleges Lawsuit Filed by Parker Waichman LLP and Co-Counsel
11. Byetta Lawyers at Gilman Law, a Leading Pharmacy Law and Defective Drug Plaintiffs’ Law Firm, Troubled by Growing Byetta Pancreatic Cancer Reports
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... ... June 27, 2016 , ... Quality metrics are proliferating ... many ways they remain in the eye of the beholder, according to experts who ... of The American Journal of Managed Care. For the full issue, click here ...
(Date:6/26/2016)... Orion, Clarkston, Michigan (PRWEB) , ... June 26, ... ... with respect to fertility once they have been diagnosed with endometriosis. These women ... intercourse but they also require a comprehensive approach that can help for preservation ...
(Date:6/25/2016)... ... ... First Choice Emergency Room , the largest network of independent freestanding emergency ... its new Mesquite-Samuell Farm facility. , “We are pleased to announce Dr. Ogunleye ... M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. , Dr. Ogunleye ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article ... are unfamiliar with. The article goes on to state that individuals are now more ... these less common operations such as calf and cheek reduction. The Los Angeles area ...
(Date:6/24/2016)... ... June 24, 2016 , ... Global law firm Greenberg Traurig, P.A. announced ... attorneys chosen by their peers for this recognition are considered among the top 2 ... received special honors as members of this year’s Legal Elite Hall of Fame: ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... , June 24, 2016 ... Market by Type (Standard Pen Needles, Safety Pen Needles), ... (Insulin, GLP-1, Growth Hormone), Mode of Purchase (Retail, Non-Retail) ... MarketsandMarkets, This report studies the market for the forecast ... to reach USD 2.81 Billion by 2021 from USD ...
(Date:6/23/2016)... , June 23, 2016  MedSource announced ... as its e-clinical software solution of choice.  This ... best possible value to their clients by offering ... The preferred relationship establishes nowEDC as the EDC ... for MedSource,s full-service clients.  "nowEDC has long been ...
(Date:6/23/2016)... a startling report released today, National Safety Council research ... proven plan to eliminate prescription opioid overdoses. Prescription Nation ... tackling the worst drug crisis in recorded U.S. history, assigned a ... , New Mexico , Tennessee ... failing states, three – Michigan , ...
Breaking Medicine Technology: